tbuckley/cabot-search huggingface dataset:
Updated overall survival (OS) and exploratory analysis from the randomized, phase II EVAN study of erlotinib (E) versus vinorelbine plus cisplatin (NP) as adjuvant therapy in Chinese patients with stage IIIA EGFR+ NSCLC.
Authors: Dongsheng Yue, Shi-Dong Xu, Qun Wang, Xiaofei Li, Yi Shen, Heng Zhao, Chun Chen, Weimin Mao, Wei Liu, Junfeng Liu, Lan-Jun Zhang, Haitao Ma, Qiang Li, Yue Yang, Yongyu Liu, Haiquan Chen, Zhenfa Zhang, Bin Zhang, Fuyu Gong, Changli Wang
Journal: Journal of Clinical Oncology (2021)

8520 Background: The EVAN study of E vs NP in stage III EGFR+ NSCLC has met its primary endpoint and been previously published: 2-year disease-free survival was 81.4% (95% CI, 69.6–93.1) in E group vs 44.6% (95% CI, 26.9-62.4) in NP group (HR, 1.823; 95% CI, 1.194–2.784; P=0.0054). We report 5-year OS and exploratory results from EVAN with a further 43 month follow up (cutoff date: Jan 6, 2021). Methods: Patients with stage IIIA EGFR+ NSCLC were randomized assigned (1:1) into either E arm (n=51, 150mg/day) or NP arm (n=51, vinorelbine 25mg/m 2 on day 1, 8 and cisplatin 75mg/m 2 on day 1 of a 21-day cycle). In order to explore the relationship between patient benefits and co-occurring variants, 47 patients received whole exome sequencing (WES) analysis (E, n=24; NP, n=23). Results: Median follow-up time was 54.8 months for E and 63.9 months for NP. E improved OS and 5-year survival rate compared with NP in ITT population. The median OS was 84.2m (95% CI, 78.1,-) with E vs 61.1m (95% CI, 39.6-82.1) with NP (HR, 0.318; 95% CI, 0.151-0.670). The 5-year survival rates were 84.8% (95%CI, 72.0-97.6) and 51.1% (95% CI, 34.7-67.5), respectively. In the WES analysis, we found that the most frequent genes with co-occurring variants at baseline were TP53, MUC16, FAM104B, KMT5A and DNAH9, and additional EGFR variants, each with similar prevalence regardless of EGFR-activating mutation subgroup. Moreover, in the erlotinib-treated patients, the SNP mutation of UBXN11 was associated with significantly worse DFS (P=0.0111). Conclusions: This is the first randomized study of EGFR-TKI to demonstrate a clinically meaningful improvement in OS vs chemotherapy in stage III EGFR+ NSCLC (5-year survival rate 84.8% in E vs 51.1% in NP). The co-occurring variants at baseline may be associated with reduced DFS. Further studies are required to confirm our results (EVAN, NCT01683175). Clinical trial information: NCT01683175.
501P Analysis of clinical characteristics and survival trends of patients with metastatic colorectal cancer (mCRC) receiving ≥3 lines of treatment
Authors: M. Bringas Beranek, N. Gutiérrez Alonso, J. Soto Alsar, A. Gutiérrez Ortiz de la Tabla, C. López Jiménez, M. Alva Bianchi, R. Jiménez Rodríguez, R. Martín Lozano, L. Ortega Morán, G. Torres Pérez-Solero, A. Muñoz Martín, A. Calvo, M. Blanco, M. Arregui Valles, M.I. Aparicio Salcedo, M. Martin, P. García-Alfonso
Journal: Annals of Oncology (2021)
282P Methylthioadenosine phosphorylase (MTAP) genomic loss in ERBB2 amplified (amp) and mutated (mut) (ERBB2+) metastatic breast cancer (MBC)
Authors: A. Sivapiragasam, N.A. Danziger, K. Mcgregor, E. Sokol, J.S. Ross
Journal: Annals of Oncology (2021)
1709P Prediction of febrile neutropenia (FN), hospitalization (Hosp) rates, and infection (Inf) rates in chemotherapy-induced neutropenia (CIN) patients (pts) treated with the plinabulin and pegfilgrastim combination (Plin+Peg) using a meta-analysis (MA)-based tool
Authors: S. Ogenstad, D. Blayney, L. Huang, R. Mohanlal
Journal: Annals of Oncology (2021)
947P Updated survival and secondary safety and efficacy analyses from CA 209-678: A phase II open-label single-centre study of Y90-radioembolisation (Y90) in combination with nivolumab in Asian patients (pts) with advanced hepatocellular carcinoma (aHCC)
Authors: J.J.X. Lee, S.H. Tan, T.P. Hennedige, K.S.H. Loke, A. Gogna, D.C.E. Ng, S. Leong, S.Y. Lee, A.K.T. Tong, W.Y. Tham, W. Xie, K.D. Zhuang, S.X. Chan, P. Kumar, J.H. Kam, C.H. Thng, L. Ooi, C.Y. Chan, S.P. Choo, D. Tai
Journal: Annals of Oncology (2021)
1667TiP Durvalumab plus platinum-etoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): A Spanish phase IIIb single arm, real-world study
Authors: L. Paz-Ares, E. Arriola, M.R. Garcia Campelo, M.P. Diz Tain, M.C. Marti Blanco, A.L. Moreno Vega, L. Leon-Mateos, V. Gutierrez Calderon, A. Sanchez Hernandez, J.M. Oramas Rodriguez, M. Majem, C. Aguado de la Rosa, R. Alvarez Cabellos, J.L. Marti Ciriquian, V. Amezcua, J.L. Firvida Perez, Á. Callejo Mellén, L. Baez, D. Isla
Journal: Annals of Oncology (2021)
Abstract 10862: Prediction of the Response to Beta-blocker Therapy in Patients With Dilated Cardiomyopathy Using T1 Mapping on Cardiovascular Magnetic Resonance
Authors: Yumiko Kanzaki, Yusuke Nishida, Daichi Maeda, Kosuke Tsuda, Takahide Ito, Koichi Sohmiya, Masaaki Hoshiga
Journal: Circulation (2019)

Introduction: In some patients with heart failure, administration of beta-blockers can improve left ventricular (LV) function and reduce morbidity and mortality. Novel T1 mapping on MRI provides a ...
Complaints about politicians’ use of statistics rise sharply
Authors: Adrian O’Dowd
Journal: BMJ (2021)

Statistics experts have questioned politicians’ and civil servants’ use of data dozens of times over the past year as complaints about how statistics are used have almost tripled in 12 months.

The UK Statistics Authority dealt with 323 pieces of casework between 1 April 2020 and 31 March 2021, almost three times the 109 cases it had the previous year, said the watchdog in its annual report.1

Most (72%) of the 323 cases this year related to health and social care, with 97% of those related to the covid-19 pandemic, said the report, which was produced with the authority’s regulatory arm, the Office for Statistics Regulation.

The greatest proportion and more …
Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study
Authors: Juan W Valle, Arndt Vogel, Crystal S Denlinger, Aiwu Ruth He, Li-Yuan Bai, Rashida Orlova, Eric Van Cutsem, Jorge Adeva, Li-Tzong Chen, Radka Obermannova, Thomas J Ettrich, Jen-Shi Chen, Harpreet Wasan, Allicia C Girvan, Wei Zhang, Jiangang Liu, Chunlao Tang, Philip J Ebert, Amit Aggarwal, Samuel C McNeely, Brian A Moser, Joana M Oliveira, Roberto Carlesi, Richard A Walgren, Do-Youn Oh
Journal: The Lancet Oncology (2021)
Bruton’s Tyrosine Kinase Inhibition as an Emerging Therapy in Systemic Autoimmune Disease
Authors: Stefan F. H. Neys, Jasper Rip, Rudi W. Hendriks, Odilia B. J. Corneth
Journal: Drugs (2021)

Systemic autoimmune disorders are complex heterogeneous chronic diseases involving many different immune cells. A significant proportion of patients respond poorly to therapy. In addition, the high burden of adverse effects caused by "classical" anti-rheumatic or immune modulatory drugs provides a need to develop more specific therapies that are better tolerated. Bruton's tyrosine kinase (BTK) is a crucial signaling protein that directly links B-cell receptor (BCR) signals to B-cell activation, proliferation, and survival. BTK is not only expressed in B cells but also in myeloid cells, and is involved in many different signaling pathways that drive autoimmunity. This makes BTK an interesting therapeutic target in the treatment of autoimmune diseases. The past decade has seen the emergence of first-line BTK small-molecule inhibitors with great efficacy in the treatment of B-cell malignancies, but with unfavorable safety profiles for use in autoimmunity due to off-target effects. The development of second-generation BTK inhibitors with superior BTK specificity has facilitated the investigation of their efficacy in clinical trials with autoimmune patients. In this review, we discuss the role of BTK in key signaling pathways involved in autoimmunity and provide an overview of the different inhibitors that are currently being investigated in clinical trials of systemic autoimmune diseases, including rheumatoid arthritis and systemic lupus erythematosus, as well as available results from completed trials.
1368TiP EPROPA: The European program for routine testing of patients with advanced lung cancer
Authors: F. Passiglia, F. Tabbò, L. Righi, P. Bironzo, M.L. Reale, A. Listi, C. Sini, S. Vallone, F. Arizio, N.M. Secen, L. Paz-Ares, E. Felip, A. Araújo, H. Linardou, K. Mohorcic, L. Mazilu, E. Szmytke, A. Comanescu, G. Scagliotti, S. Novello
Journal: Annals of Oncology (2021)
Quantitative characterization of the human retinotopic map based on quasiconformal mapping
Authors: Duyan Ta, Yanshuai Tu, Zhong-Lin Lu, Yalin Wang
Journal: Medical Image Analysis (2021)

The retinotopic map depicts the cortical neurons' response to visual stimuli on the retina and has contributed significantly to our understanding of human visual system. Although recent advances in high field functional magnetic resonance imaging (fMRI) have made it possible to generate the in vivo retinotopic map with great detail, quantifying the map remains challenging. Existing quantification methods do not preserve surface topology and often introduce large geometric distortions to the map. In this study, we developed a new framework based on computational conformal geometry and quasiconformal Teichmüller theory to quantify the retinotopic map. Specifically, we introduced a general pipeline, consisting of cortical surface conformal parameterization, surface-spline-based cortical activation signal smoothing, and vertex-wise Beltrami coefficient-based map description. After correcting most of the violations of the topological conditions, the result was a "Beltrami coefficient map" (BCM) that rigorously and completely characterizes the retinotopic map by quantifying the local quasiconformal mapping distortion at each visual field location. The BCM provided topological and fully reconstructable retinotopic maps. We successfully applied the new framework to analyze the V1 retinotopic maps from the Human Connectome Project (n=181), the largest state of the art retinotopy dataset currently available. With unprecedented precision, we found that the V1 retinotopic map was quasiconformal and the local mapping distortions were similar across observers. The new framework can be applied to other visual areas and retinotopic maps of individuals with and without eye diseases, and improve our understanding of visual cortical organization in normal and clinical populations.
928TiP Induction versus adjuvant gemcitabine/cisplatin in locally advanced non-metastatic nasopharyngeal carcinoma: A randomised phase III trial
Authors: S.A. Masoud, M. Elsherify, E. Elmoghazy, H. Sakr, M. Ashour Metwaly, J. Shete, S. Rajan, K. Al Saleh, A. Hussein
Journal: Annals of Oncology (2021)
Mind the gap: The mediating role of emotion mechanisms in social bonding through musical activities
Authors: Patrik N. Juslin
Journal: Behavioral and Brain Sciences (2021)

Abstract I support the music and social bonding (MSB) framework, but submit that the authors' predictions lack discriminative power, and that they do not engage sufficiently with the emotion mechanisms that mediate between musical features and social bonding. I elaborate on how various mechanisms may contribute, in unique ways, to social bonding at various levels to help account for the socio-emotional effects of music.
1020P MPT-0118 a clinical drug candidate to assess Treg reprogramming via MALT1 blockade
Authors: P. Keller, I. Mazo, Y. Gao, V. Reddy, F. Caballero, B. Stephens, J.E. Marvin, A. Fu, Y. Sun, R.W. Jenkins, U.H. von Andrian, T.R. Mempel
Journal: Annals of Oncology (2021)
637P Biochemical response (PSA0) and testosterone (T) recovery in Metacure, a multi-arm multi-modality (MM) therapy (tx) for very high risk localized (HRL) and low volume metastatic (LVM) prostatic adenocarcinoma
Authors: M.Y. Teo, S. McBride, A. Gopalan, H. Benoliel, J.A. Eastham, A. Goh, R. Szmulewitz, A.K. Morgans, G. Bubley, S. Gupta, E.A. Klein, P. Nguyen, A.S. Kibel, A. Wagner, I.D. Kaplan, S.E. Eggener, S.L. Liauw, M.E. Taplin, H. Scher
Journal: Annals of Oncology (2021)
Porphyromonas gingivalis exacerbates ulcerative colitis via Porphyromonas gingivalis peptidylarginine deiminase
Authors: Xida Zhao, Jingbo Liu, Chong Zhang, Ning Yu, Ze Lu, Shuwei Zhang, Yuchao Li, Qian Li, Junchao Liu, Dongjuan Liu, Yaping Pan
Journal: International Journal of Oral Science (2021)

Abstract Ulcerative Colitis (UC) has been reported to be related to Porphyromonas gingivalis ( P. gingivalis ). Porphyromonas gingivalis peptidylarginine deiminase (PPAD), a virulence factor released by P. gingivalis , is known to induce inflammatory responses. To explore the pathological relationships between PPAD and UC, we used homologous recombination technology to construct a P. gingivalis strain in which the PPAD gene was deleted (Δ ppad ) and a Δ ppad strain in which the PPAD gene was restored (comΔ ppad ). C57BL/6 mice were orally gavaged with saline, P. gingivalis , Δ ppad, or comΔ ppad twice a week for the entire 40 days (days 0−40), and then, UC was induced by dextran sodium sulfate (DSS) solution for 10 days (days 31−40). P. gingivalis and comΔ ppad exacerbated DDS-induced colitis, which was determined by assessing the parameters of colon length, disease activity index, and histological activity index, but Δ ppad failed to exacerbate DDS-induced colitis. Flow cytometry and ELISA revealed that compared with Δ ppad , P. gingivalis , and comΔ ppad increased T helper 17 (Th17) cell numbers and interleukin (IL)-17 production but decreased regulatory T cells (Tregs) numbers and IL-10 production in the spleens of mice with UC. We also cocultured P. gingivalis , Δ ppad , or comΔ ppad with T lymphocytes in vitro and found that P. gingivalis and comΔ ppad significantly increased Th17 cell numbers and decreased Treg cell numbers. Immunofluorescence staining of colon tissue paraffin sections also confirmed these results. The results suggested that P. gingivalis exacerbated the severity of UC in part via PPAD.
1297P RATIONALE 307: Tislelizumab (TIS) plus chemotherapy (chemo) vs chemo alone as first-line (1L) treatment for advanced squamous non-small cell lung cancer (sq NSCLC) in patients (pts) who were smokers vs non-smokers
Authors: X. Yu, J. Wang, S. Lu, J. Zhao, Y. Yu, C. Hu, G. Feng, K. Ying, W. Zhuang, J. Zhou, J. Wu, S.J. Leaw, X. Lin, J. Zhang
Journal: Annals of Oncology (2021)
1375P SHR-1701, a novel bifunctional anti-PD-L1/TGF-βRII agent, for pretreated recurrent/refractory (r/r) gastric cancer (GC): Data from a first-in-human phase I study
Authors: D. Liu, S. Luo, M. Li, T. Liu, M. Ge, Y. Wang, H. Jiang, Y. Liu, X. Xiang, X. Zhang, L. Wang, P. Liu, L. Shen
Journal: Annals of Oncology (2021)
627P Phase II neoadjuvant trial of the anti–B7-H3 antibody, enoblituzumab, in men with localized prostate cancer: Safety, efficacy and immune correlates
Authors: E. Shenderov, A. De Marzo, T. Lotan, H. Wang, M.E. Allaf, K. Boudadi, C. Chapman, T. O'Neal, F. Chen, P. Moore, J. Muth, K. Sorg, A.M. White, S.E. Church, T. Bivalacqua, A.E. Ross, C.P. Pavlovich, C.G. Drake, D. Pardoll, E.S. Antonarakis
Journal: Annals of Oncology (2021)
Preventing Death Rattle With Prophylactic Subcutaneous Scopolamine Butylbromide
Authors: Jared R. Lowe, Laura C. Hanson
Journal: JAMA (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
1487TiP A randomized non-comparative phase II study of maintenance therapy with FOLFIRI alone or in combination with Tedopi vaccine after induction therapy with FOLFIRINOX in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (TEDOPAM – D17-01 PRODIGE 63 STUDY)
Authors: M. Hilmi, V. Hautefeuille, A. Lambert, M.L. Garcia Larnicol, D. Vernerey, C. Neuzillet
Journal: Annals of Oncology (2021)
187P Relationship between immune profile and immunophenotype in early breast cancer
Authors: C.M.M. Bravo, R. Villatoro, D. Pérez, I. Zarcos, L. Robles, I. Rodrigo, E. Pérez-Ruiz, J. Alcaide, F. Rivas-Ruiz, V. Navarro, M. Robles, A. Galeote, P. Cantizani, C. Quero, A. Rueda Dominguez
Journal: Annals of Oncology (2021)
<i>β</i>‐Catenin Limits Osteogenesis on Regenerative Materials in a Stiffness‐Dependent Manner
Authors: Qi Zhou, Xiaoyan Ren, Michelle K. Oberoi, Meiwand Bedar, Rachel M. Caprini, Marley J. Dewey, Vasiliki Kolliopoulos, Dean T. Yamaguchi, Brendan A. C. Harley, Justine C. Lee
Journal: Advanced Healthcare Materials (2021)

Targeted refinement of regenerative materials requires mechanistic understanding of cell-material interactions. The nanoparticulate mineralized collagen glycosaminoglycan (MC-GAG) scaffold is shown to promote skull regeneration in vivo without additive exogenous growth factors or progenitor cells, suggesting potential for clinical translation. This work evaluates modulation of MC-GAG stiffness on canonical Wnt (cWnt) signaling. Primary human bone marrow-derived mesenchymal stem cells (hMSCs) are differentiated on two MC-GAG scaffolds (noncrosslinked, NX-MC, 0.3 kPa vs conventionally crosslinked, MC, 3.9 kPa). hMSCs increase expression of activated β-catenin, the major cWnt intracellular mediator, and the mechanosensitive YAP protein with near complete subcellular colocalization on stiffer MC scaffolds. Overall Wnt pathway inhibition reduces activated β-catenin and osteogenic differentiation, while elevating BMP4 and phosphorylated Smad1/5 (p-Smad1/5) expression on MC, but not NX-MC. Unlike Wnt pathway downregulation, isolated canonical Wnt inhibition with β-catenin knockdown increases osteogenic differentiation and mineralization specifically on the stiffer MC. β-catenin knockdown also increases p-Smad1/5, Runx2, and BMP4 expression only on the stiffer MC material. Thus, while stiffness-induced activation of the Wnt and mechanotransduction pathways promotes osteogenesis on MC-GAG, activated β-catenin is a limiting agent and may serve as a useful target or readout for optimal modulation of stiffness in skeletal regenerative materials.
Hepatocellular Carcinoma Immunotherapy
Authors: Rubens Copia Sperandio, Roberto Carmagnani Pestana, Beatriz Viesser Miyamura, Ahmed O. Kaseb
Journal: Annual Review of Medicine (2021)

Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and the third leading cause of cancer-related death worldwide. Single-agent anti-PD-1 immune checkpoint inhibitors (ICIs) demonstrated promising efficacy in early-phase trials, a finding that was not confirmed in phase III studies. The combination of atezolizumab (an anti-PD-L1 ICI) with bevacizumab (an anti-VEGF antibody) was approved as first-line therapy in 2020, however, with significant improvement in response rate, progression-free survival, and overall survival in comparison with the previous standard of care, sorafenib. Numerous ongoing clinical trials are assessing ICIs in combination with each other or with targeted agents, and also in earlier stages with local therapies. This review summarizes the latest concepts in the use of ICIs for the management of HCC.
Additional points to consider before incorporating the Food and Drug Administration–approved therapies for systemic sclerosis–associated interstitial lung disease: comment on the article by Khanna et al
Authors: Markus Bredemeier
Journal: Arthritis & Rheumatology (2021)

Disclosure Form Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
618P Apalutamide (APA) for advanced prostate cancer in older patients (pts): Combined analysis of TITAN &amp; SPARTAN
Authors: J. Shen, S. Chowdhury, N. Agarwal, L.I. Karsh, S. Oudard, B.A. Gartrell, S. Feyerabend, F. Saad, C.M. Pieczonka, K.N. Chi, S.D. Brookman-May, B. Rooney, A. Bhaumik, A. Londhe, S.A. McCarthy, K.B. Bevans, S.D. Mundle, E.J. Small, M.R. Smith, J.N. Graff
Journal: Annals of Oncology (2021)
CLL-Specific B Cell Receptor Immunoglobulin Stereotypes Are Very Infrequent in Low Count Monoclonal B Cell Lymphocytosis: Implications for Disease Ontogeny
Authors: Andreas Agathangelidis, Chrysi Galigalidou, Lydia Scarfo, Alessandra Rovida, Maria Gounari, Fotis Psomopoulos, Pamela Ranghetti, Katerina Gemenetzi, Frederic Davi, Kostas Stamatopoulos, Anastasia Hadzidimitriou, Paolo Ghia
Journal: Blood (2017)
1444P Intravenous (IV) patient-controlled analgesia (PCA) vs oral opioid to maintain analgesia for severe cancer pain after successful hydromorphone (HM) titration: A multi-center, phase II randomized trial (HMORCT09-2)
Authors: R. Lin, J. Zhu, X. Li, X. Lv, J. Liu, M. Wu, Y. Luo, M. Lu, H. Chen, H. Zou, Z. Zhang, S. Lin, M. Zhou, S. Zhao, C. Huang
Journal: Annals of Oncology (2021)
1639P Impact of COVID-19 on ongoing oncological and hematological treatment strategy
Authors: A. Bayle, K. Ouali, E. Colomba, N. Ibrahimi, S. Foulon, B. Gachot, C. Willekens, A. Stoclin, M. Merad, F. Griscelli, R. Sun, S. Ammari, J-M. Michot, F. André, F. Scotté, B. Besse, J-C. Soria, F. Barlesi, L. Albiges, F. Pommeret
Journal: Annals of Oncology (2021)
CN47 Spanish Oncology Nursing Society efforts during COVID-19 pandemic
Authors: N. Domenech-Climent, J.C. de la Torre-Montero, N. Gil Gomez, M.A. Peñuelas Saiz, I. Magallón Pedrera, R. Cumplido Corbacho, J.M. Gavala Arjona, P. Beorlegui Murillo, J. Serra López, G. Gonzalez Monterrubio
Journal: Annals of Oncology (2021)
1038MO Intracranial activity of encorafenib and binimetinib followed by radiotherapy in patients with BRAF mutated melanoma and brain metastasis: Preliminary results of the GEM1802/EBRAIN-MEL phase II clinical trial
Authors: I. Marquez-Rodas, A. Arance, M.A. Berciano Guerrero, R. Díaz Beveridge, M.D.C. Alamo, A. Garcia Castaño, M. Gonzalez Cao, J. Vidal, T. Puertolas Hernandez, A. Soria, C. Aguado de la Rosa, P. Sánchez Mauriño, I. Valduvieco, R. Delgado Rico, A. Conde, P. Foro, P.J. Prada, E. Puertas, A. Alvarez Gonzalez, A. Berrocal
Journal: Annals of Oncology (2021)
565TiP A phase I/II dose-escalation and expansion study of ZN-c5, an oral selective estrogen receptor degrader (SERD), as monotherapy and in combination with palbociclib in patients with advanced estrogen receptor (ER)+/HER2- breast cancer
Authors: V. Abramson, H.M. Linden, K. Crew, J. Mortimer, J. Alidzanovic, J. Nangia, R. Layman, Z.J. Vranjes, Z. Andric, M. Milovic-Kovacevic, J. Trifunovic, Y. Karchmit, J. Suarez, M. Suster, M. Ptaszynski, P. Chalasani
Journal: Annals of Oncology (2021)
1443MO Differences in hematologists’ and palliative care physicians’ recommended indications and opinions on transfusion therapy for patients with hematological malignancy post-anticancer therapy
Authors: Y. Hattori, T. Miura, Y. Uehara, K. Kosugi, T. Terada, M. Natsume, Y. Shimotsuura, M. Yajima, C. Hashimoto, Y. Matsumoto
Journal: Annals of Oncology (2021)